![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhQSFJPZEv8vnG2qXx9i5xD8Qopk6vsp_dwD0SbbX_rQfZIcY24Qp9v3XDsGLPQGNEUqD5p6ysCImyeSEHDJEiyLc6IWNHoOdGLcmBEa-BczdwpmQhh-nh7N9INT-t3wn9upGPLHLfhX_rw/s200/logo+clinical+trials.gif)
The primary aim of this study is to assess the feasibility of long-acting injectable naltrexone provided through primary care (LAN/PC) versus long-acting injectable naltrexone in the specialized chemical dependence clinic (LAN/CDC). The secondary aim is to obtain preliminary assessments of the relative effectiveness of long-acting injectable naltrexone in primary care versus in the chemical dependence clinic.
This study is currently recruiting patients.
Verified by State University of New York - Upstate Medical University March 2007
Sponsors and Collaborators: | State University of New York - Upstate Medical University |
---|---|
Information provided by: | State University of New York - Upstate Medical University |
________________________________________________________________